--Company Advances Product Candidate Pipeline—
--Announces Preliminary Results from Virology Study--
BERWYN, Pa.--(BUSINESS WIRE)--#earnings--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive product candidates for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the quarter ended June 30, 2022, and other recent developments.
"We continue to advance our product candidate pipeline focused on pain, CNS and viral barrier indications," stated Anthony P. Mack, Chairman and CEO of Virpax. "AnQlar's preclinical studies continue to progress; we believe one of our preclinical virology studies shows an appropriate level of virus deactivation for a prophylactic viral barrier product candidate. We have a number of studies ongoing and expect to be reporting some results later this year.
"As we have previously stated, we are engaging in activities to potentially extend our cash runway as we move our product candidates forward. As part of this effort, we are evaluating grant opportunities and applying to those where we believe we have a reasonable chance of being selected. We recently announced and entered into a cooperative research and development agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to evaluate Probudur™, our wound site injectable product candidate that has demonstrated at least 96 hours of pain control in pre-clinical trials. The USAISR is the U.S. Department of Defense's (DOD) primary laboratory for developing solutions for trauma and critical care challenges in combat injuries and casualties," continued Mr. Mack.
"We engaged Prequient Inc., a consulting firm with extensive experience in the Consumer Self-Care or over-the-counter (OTC) marketplace. The Prequient team has been instrumental in analyzing the consumer proposition and assessing alternative regulator pathways such as our switch to an OTC pathway for Epoladerm™, and the recently announced OTC medical device pathway for AnQlar. We believe being able to obtain potential approval for an OTC product or device should be less expensive and provide us with a faster drug development timeline and faster global approval track than the Rx prescription pathway that we originally were pursuing.
"Our expertise is in the prescription drug market, and we plan to develop our Rx product candidates and commercialize them in the U.S. However, we intend to license our OTC product candidates to a company that specializes in the Consumer Self-Care market. We believe combining the potential revenue from licensing these OTC product candidates to third parties with the potential licensing of our prescription product candidates outside the U.S., may allow us to offset a portion of our R&D expenses as we continue to grow," concluded Mr. Mack.
RECENT DEVELOPMENTS
- On April 26, 2022, Virpax announced the successful completion of its initial preclinical studies for VRP324, the Company's nasal product candidate to manage seizures associated with epilepsy in children and adults. Results from this PK study demonstrated high concentrations of CBD in the brain and confirmed higher levels of CBD in the brain versus the plasma.
- On May 5, 2022, Virpax announced that it has entered into a cooperative research and development agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to evaluate Virpax's Probudur™, an injectable long-acting liposomal bupivacaine in a hydrogel formulation that is injected at the wound site. Probudur is being developed to significantly reduce or eliminate the need for opioids after surgery. In pre-clinical trials, Probudur has shown pain control for at least 96 hours.
- On June 27th, Virpax announced that it will pursue a direct to OTC regulatory pathway for Epoladerm™, the Company's product candidate to treat pain associated with osteoarthritis. The direct to OTC, non-prescription regulatory pathway is expected to provide a faster drug development timeline and faster global approval track than the prescription pathway the Company had originally pursued for Epoladerm.
- Subsequent to the end of the quarter, on July 5, 2022, Virpax announced that it will pursue an OTC Intranasal Medical Device Consumer regulatory pathway for AnQlar™, the Company's product candidate being developed as a prophylactic antiviral barrier against influenza and SARS-CoV-2. The Company believes that the OTC non-prescription Medical Device pathway is more efficient than the OTC non-prescription New Drug Application pathway that was originally pursued for AnQlar.
- The Company engaged Prequient Inc., a strategic consultancy firm experienced in developing products from concept through FDA approval and launch in the Consumer Self-Care marketplace. The principals in the firm have brought numerous products to the OTC marketplace including Flonase, Claritin, Tylenol and Panadol.
FINANCIAL RESULTS FOR THE THREE ENDED JUNE 30, 2022 AND 2021
Three Months Ended June 30, 2022 and 2021
Operating Expenses
General and administrative expenses were approximately $2.7 million for the second quarter of 2022, an increase of about $0.7 million from the prior year's second quarter. The increase was due to legal defense costs with regard to litigation, compensation related to new hires and merit raises, insurance costs, non-executive board compensation and investor relations. These expenses were partially offset by a decrease in stock-based compensation.
Research and development expenses were approximately $3.3 million in the quarter compared to approximately $0.3 million from the prior year's second quarter. The increase in research and development expenses was primarily attributable to an increase in preclinical activities for AnQlar, Probudur and Epoladerm, a milestone payment related to VRP324, and a slight increase in preclinical and regulatory activities for Envelta.
The operating loss for the second quarter of 2022 was approximately $5.9 million, as compared to $2.3 million for the same period a year ago.
Six Months Ended June 30, 2022 and 2021
Operating Expenses
General and administrative expenses were approximately $4.4 million for the six months ended June 30, 2022, an increase of about $1.2 million as compared to the six months ended June 30, 2021. The primary reason for the increase in general and administrative costs was the result of an increase in legal defense costs with regard to litigation, an increase in salaries and wages and employee benefits related to new hires and merit increases, an increase in insurance costs related to directors' and officers' insurance, an increase in non-executive board compensation, and an increase in grant writing and grant consulting fees. This was offset by a decrease in stock based compensation.
Research and development expenses increased by approximately $5.2 million to $6.6 million for the six months ended June 30, 2022, from $1.4 million for the six months ended June 30, 2021. The increase was primarily attributable to an increase in milestone payments related to AnQlar, an increase in preclinical activity related to AnQlar's ongoing IND enabling studies, increases in preclinical and regulatory activity related to Epoladerm, an increase in preclinical work related to Probudur related to ongoing formula optimization, an increase in VRP324 mainly due to a milestone payment of $500,000 upon achieving the study aim contained within a pre-clinical animal study, and a slight increase in regulatory activities related to Envelta.
Cash Flows
Operating Activities
Cash used in operations was approximately $10.8 million for the six months ended June 30, 2022, compared to approximately $4.9 million for the six months ended June 30, 2021. The increase in cash used in operations was primarily the result of the increase in net loss and prepaid expenses and current assets, offset by an increase in accounts payable and accrued expenses.
Financing Activities
Cash provided by financing activities was approximately $15.3 million during the six months ended June 30, 2021, attributable primarily to net proceeds received from the Company's initial public offering in February 2021 of approximately $15.8 million, after deducting underwriting discounts and offering expenses. This was slightly offset by repayment in full of the Company's convertible promissory note of approximately $0.5 million in February 2021. No financing activities took place during the six months ended June 30, 2022.
At June 30, 2022, the Company had cash of approximately $26.1 million.
About Virpax Pharmaceuticals
Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop two other product candidates. PES200 is a product candidate being developed to manage post-traumatic stress disorder (PTSD) and VRP324 is a product candidate being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax recently acquired global rights to VRP324. Virpax is also seeking approval of two nonprescription product candidates. AnQlar is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™ is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit .
Forward-Looking Statement
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's planned clinical trials, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or the Company's financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the COVID-19 pandemic and the potential impact of sustained social distancing efforts, on the Company's operations, clinical development plans and timelines, including any switch to an OTC pathway for certain of the Company's product candidates, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
VIRPAX PHARMACEUTICALS, INC. |
CONDENSED BALANCE SHEETS |
| | June 30, 2022 | | December 31, 2021* |
| | (Unaudited) | | | |
ASSETS | | | | | | |
Current assets | | | | | | |
Cash | | $ | 26,061,135 | | | $ | 36,841,992 | |
Prepaid expenses and other current assets | | | 3,341,307 | | | | 2,730,444 | |
Total current assets | | | 29,402,442 | | | | 39,572,436 | |
Total assets | | $ | 29,402,442 | | | $ | 39,572,436 | |
LIABILITIES AND STOCKHOLDERS' EQUITY | | | | | | | | |
Accounts payable and accrued expenses | | $ | 2,483,373 | | | $ | 2,087,691 | |
Total current liabilities | | | 2,483,373 | | | | 2,087,691 | |
Total liabilities | | | 2,483,373 | | | | 2,087,691 | |
Commitments and contingencies | | | | | | | | |
Stockholders' equity | | | | | | | | |
Preferred stock, par value $0.00001, 10,000,000 designated shares authorized, no shares issued and outstanding | | | — | | | | — | |
Common stock, $0.00001 par value; 100,000,000 shares authorized, 11,714,565 shares issued and outstanding as of June 30, 2022; 11,714,885 shares issued and outstanding as of December 31, 2021 | | | 117 | | | | 117 | |
Additional paid-in capital | | | 60,644,576 | | | | 60,188,535 | |
Accumulated deficit | | | (33,725,624 | ) | | | (22,703,907 | ) |
Total stockholders' equity | | | 26,919,069 | | | | 37,484,745 | |
Total liabilities and stockholders' equity | | $ | 29,402,442 | | | $ | 39,572,436 | |
* | | Derived from audited financial statements |
VIRPAX PHARMACEUTICALS, INC. |
CONDENSED STATEMENTS OF OPERATIONS |
(UNAUDITED) |
| | For the Three Months Ended June 30, 2022 | | For the Three Months Ended June 30, 2021 | | For the Six Months Ended June 30, 2022 | | For the Six Months Ended June 30, 2021 |
OPERATING EXPENSES | | | | | | | | | | | | | | | | |
General and administrative | | $ | 2,645,618 | | | $ | 1,988,972 | | | $ | 4,428,031 | | | $ | 3,262,544 | |
Research and development | | | 3,258,471 | | | | 316,565 | | | | 6,599,877 | | | | 1,391,565 | |
Total operating expenses | | | 5,904,089 | | | | 2,305,537 | | | | 11,027,908 | | | | 4,654,109 | |
Loss from operations | | | (5,904,089 | ) | | | (2,305,537 | ) | | | (11,027,908 | ) | | | (4,654,109 | ) |
OTHER (EXPENSE) INCOME | | | | | | | | | | | | | | | | |
Interest expense | | | - | | | | (34,049 | ) | | | - | | | | (64,748 | ) |
Other income (expense), net | | | 19,374 | | | | (3,833 | ) | | | 6,191 | | | | (3,833 | ) |
Loss before tax provision | | | (5,884,715 | ) | | | (2,343,419 | ) | | | (11,021,717 | ) | | | (4,722,690 | ) |
Benefit from income taxes | | | — | | | | — | | | | — | | | | — | |
Net loss | | $ | (5,884,715 | ) | | $ | (2,343,419 | ) | | $ | (11,021,717 | ) | | $ | (4,722,690 | ) |
Basic and diluted net loss per share | | | $ (0.50 | ) | | | $ (0.47 | ) | | $ | (0.94 | ) | | $ | (1.06 | ) |
Basic and diluted weighted average common stock outstanding | | | 11,712,753 | | | | 4,958,999 | | | | 11,710,733 | | | | 4,454,877 | |
VIRPAX PHARMACEUTICALS, INC. |
CONDENSED STATEMENTS OF CASH FLOWS |
(UNAUDITED) |
| | For the Six Months Ended June 30, 2022 | | For the Six Months Ended June 30, 2021 |
CASH FLOWS FROM OPERATING ACTIVITIES | | | | | | | | |
Net loss | | $ | (11,021,717 | ) | | $ | (4,722,690 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |
Non-cash interest expense | | | — | | | | 64,748 | |
Stock-based compensation | | | 456,041 | | | | 691,311 | |
Change in operating assets and liabilities: | | | | | | | | |
Prepaid expenses and other current assets | | | (610,863 | ) | | | (902,649 | ) |
Accounts payable and accrued expenses | | | 395,682 | | | | (8,469 | ) |
Net cash used in operating activities | | | (10,780,857 | ) | | | (4,877,749 | ) |
CASH FLOWS FROM FINANCING ACTIVITIES | | | | | | | | |
Repayment of notes payable | | | — | | | | (493,480 | ) |
Proceeds from related party notes payable | | | — | | | | 100,000 | |
Repayment of related party notes payable | | | — | | | | (100,000 | ) |
Offering costs related to initial public offering | | | — | | | | (2,216,793 | ) |
Proceeds from initial public offering of common stock | | | — | | | | 18,000,000 | |
Net cash provided by financing activities | | | — | | | | 15,289,727 | |
Net change in cash | | | (10,780,857 | ) | | | 10,411,978 | |
Cash, beginning of period | | | 36,841,992 | | | | 54,796 | |
Cash, end of period | | $ | 26,061,135 | | | $ | 10,466,774 | |
Supplemental disclosure of cash and non-cash financing activities | | | | | | | | |
Cash paid for interest | | $ | — | | | $ | 34,707 | |
Cash paid for taxes | | $ | — | | | $ | — | |
Contacts Christopher M. Chipman, CPA
Chief Financial Officer
cchipman@virpaxpharma.com
610-727-4597
Or
Betsy Brod
Affinity Growth Advisors
betsy.brod@affinitygrowth.com
212-661-2231
-企業が製品候補パイプラインを推進-
-ウイルス学的研究の初歩的な結果の発表--
ベヴィンペンシルバニア州-Virpax®製薬会社(“ヴィパイックス”や“会社”)疼痛コントロール、創傷後ストレス障害、中枢神経系(CNS)障害とウイルスバリア適応のための非依存性候補製品を専門に開発した会社は、今日2022年6月30日までの四半期財務業績とその他の最新発展を発表した
Virpax会長兼最高経営責任者のAnthony P.Mack氏は“私たちは引き続き私たちの候補製品ラインを推進し、痛み、中枢神経系、ウイルスバリアの適応に重点を置いている。AnQlarの臨床前研究は引き続き進展している;私たちの臨床前ウイルス学的研究は、予防性ウイルスバリア製品候補製品にとってウイルス不活化レベルが適切であることを示していると信じている。私たちはいくつかの研究を行っており、今年の遅い時期にいくつかの結果を報告する予定である
私たちが前に言ったように、私たちは私たちの候補製品を推進すると同時に、私たちの現金滑走路を拡大する活動を行っています。この努力の一部として、私たちは援助機会を評価し、合理的な機会があると考えている会社に申請しています。私たちは最近、プロブドールを評価するために米陸軍外科研究所(USAISR)と共同研究開発協定(CRADA)を発表し、締結しました™我々の創傷部位注射可能製品候補は、臨床前試験において少なくとも96時間の疼痛制御が証明されている。USAISRはアメリカ国防省(DOD)の主要な実験室であり、戦闘死傷方面の創傷と危篤看護挑戦に対する解決方案を開発するために用いられる
消費者のセルフケアや非処方(OTC)市場で豊富な経験を持つコンサルティング会社であるPquireent Inc.を招聘しました。Pquireentチームは、消費者の主張を分析し、代替調節経路を評価する上で重要な役割を果たしています。例えば、EpoladermのOTC経路に切り替えるなど、™最近発表されたAnQlarのOTC医療機器経路。私たちは、OTC製品またはデバイスの潜在的な承認を得ることができることは、より安くなり、私たちが最初に追求したRx処方薬経路よりも速い薬物開発スケジュールとより速い世界的承認経路を提供してくれるはずだと信じている
私たちの専門は処方薬市場であり、私たちは私たちの処方薬候補製品を開発し、アメリカで商業化することを計画しています。しかし、私たちは私たちの非処方薬候補製品を消費者の自己ケア市場に専門的な会社に許可するつもりです。私たちは、これらの候補非処方薬製品を第三者に許可する潜在的な収入と、私たちの候補処方薬製品のアメリカ以外の潜在的な許可を組み合わせることで、成長を続ける時に研究開発費の一部を相殺するかもしれないと信じています
最近の発展
- 2022年4月26日、VirpaxはVRP 324の初歩的な臨床前研究の完成に成功したことを発表し、VRP 324は同社が児童と成人てんかん発作を治療するための鼻腔製品候補薬物である。このPK研究の結果,CBDは脳中濃度が高く,脳中のCBDレベルが血漿よりも高いことが確認された
- 2022年5月5日、VIPAXは、長時間作用性リポソーム布比カインを注射するヒドロゲル製剤であるVIPAXのProbudur≡を評価するために、米国陸軍外科研究所と共同研究開発協定を締結したと発表した。Probudurは手術後のオピオイドに対する需要を著しく減少または除去するために開発されている。前臨床試験では,Probudurは少なくとも96時間の疼痛コントロールを示した
- 六月二十七日これは…。Virpaxは、骨関節炎関連疼痛を治療する同社の製品Epoladerm™のために、場外取引に直接規制する方法を求めると発表した。会社が最初にEpoladermのために求めた処方薬経路と比較して、非処方薬に直接供給される非処方薬規制経路は、より速い薬物開発スケジュールとより速い世界的承認経路を提供することが予想される
- 四半期終了後,すなわち2022年7月5日,VIPAXは,同社が開発しているインフルエンザやSARS−CoV−2予防のための候補製品ANQLARについて非処方鼻内医療機器消費者規制経路を求めることを発表した。同社は,OTC非処方薬医療機器経路はAnQlarが最初に追求したOTC非処方薬新薬応用経路よりも有効であると考えている
- 同社はPquireent Inc.を招聘し,概念からFDAに承認され,消費者セルフケア市場で製品を発売する上で経験豊富な戦略コンサルティング会社である。同社の担当者は、Flonase、Claritin、Tylenol、Panadolを含む多くの製品を場外取引市場に投入している
2022年と2021年6月30日までの3社の財務実績
2022年と2021年6月30日までの3ヶ月
運営費
2022年第2四半期の一般·行政費は約270万ドルで、前年第2四半期より約70万ドル増加した。増加の原因は,訴訟に関する法的弁護コスト,新入社員や功績向上に関する補償,保険コスト,非執行取締役会補償と投資家関係である。このような費用は株に基づく給与減少によって部分的に相殺される
同四半期の研究·開発支出は約330万ドルだったが、昨年第2四半期の研究·開発支出は約30万ドルだった。研究·開発費の増加は主にAnQlar,Probudur,Epoladermの臨床前活動の増加によるものであり,VRP 324に関する記念碑的支払いであり,Enveltaの臨床前と規制活動がやや増加している
2022年第2四半期の運営損失は約590万ドルだったが、前年同期は230万ドルだった
2022年と2021年6月30日までの6ヶ月間
運営費
2022年6月30日までの6カ月間の一般·行政費は約440万ドルで、2021年6月30日までの6カ月に比べて約120万ドル増加した。一般·行政費増加の要因は,訴訟に関する法的弁護費の増加,新規雇用や業績増加に関する賃金,賃金,従業員福祉の増加,役員や上級管理者保険に関する保険費用の増加,非執行取締役会の報酬増加,贈与執筆や贈与相談費の増加である。これは株に基づく報酬の減少によって相殺される
2022年6月30日までの6カ月間で、研究開発費は約520万ドル増加し、2021年6月30日までの6カ月間の140万ドルから660万ドルに増加した。この増加は主にAnQlarに関するマイルストーン支払いの増加,AnQlarが行っているINDイネーブル研究に関する臨床前活動の増加,Epoladermに関する臨床前と規制活動の増加,Probudurに関する進行中のレシピ最適化に関する臨床前作業の増加,VRP 324の増加は,主に臨床前動物研究に含まれる研究目標達成後のマイルストーン支払い50万ドル,およびEnveltaに関する規制活動がやや増加したためである
キャッシュフロー
経営活動
2022年6月30日までの6カ月間、運営に使用された現金は約1080万ドルだったが、2021年6月30日までの6カ月で約490万ドルだった。業務用現金増加の主な原因は純損失,前払い費用,流動資産の増加であるが,売掛金と売掛金の増加はこの増加を相殺している
融資活動
2021年6月30日までの6カ月間で、融資活動が提供した現金は約1530万ドルで、引受割引や発売費用を差し引いた後、会社が2021年2月に初めて公募株で受け取った純収益は約1580万ドルだったことが主な原因だ。2021年2月、会社は約50万ドルの転換可能な元票を全額返済し、この影響をわずかに相殺した。2022年6月30日までの6ヶ月間、融資活動は何も発生しなかった
同社は2022年6月30日現在、約2610万ドルの現金を持っている
Virpax製薬会社について
Virpaxはブランド,非嗜癖性疼痛管理製品を開発しており,候補製品はそのノウハウを用いて薬物送達を最適化·配向させている。Virpaxは当初,FDAが2種類の異なる特許薬物送達プラットフォームを使用した処方薬候補薬の2種類の承認を求めていた。Probudur≡は術後疼痛の治療のために開発されているブピバカイン単回注射リポソーム製剤であり、Envelta VIは癌に関連する疼痛を含む急性および慢性疼痛を治療するために開発されている鼻腔分子エンベロープ脳エンドルフィン製剤である。Virpaxはその鼻腔分子エンベロープ技術(MET)を用いて他の2つの候補製品を開発している。PES 200は創傷後ストレス障害(PTSD)の治療のために開発されている候補製品であり,VRP 324は開発中の薬物級カンナビノール(CBD)鼻投与のための候補製品であり,まれな小児てんかんの治療に用いられている。Virpaxは最近VRP 324の世界的な権利を獲得した。Virpaxはまた二つの非処方薬候補製品の承認を求めている。AQLARはインフルエンザやSARS−CoV−2によるウイルス複製を抑制するために開発されているが,Epoladermオスミウムは骨関節炎に関連する痛みの治療のために開発されている局所ジクロフェナク噴霧膜製剤である。もっと情報を知りたいのですが、アクセスしてください
前向きに陳述する
本プレスリリースは、会社計画の臨床試験、製品開発、臨床および規制スケジュール、市場機会、競争地位、可能または仮定の将来の経営結果、商業戦略、潜在的成長機会、および他の予測陳述に関連する陳述を含む、1933年証券法第27 A節および1934年証券取引法第21 E節および改正された個人証券訴訟改革法に言及されたいくつかの展望的陳述を含む。これらの展望性陳述は、私たちが経営している業界と市場に対する現在の予想、推定、予測と予測、および経営陣の現在の信念と仮定に基づいている
これらの表現は、“予想”、“予想”、“意図”、“計画”、“信じ”、“推定”、“潜在”、“予測”、“プロジェクト”、“すべき”、“将”および同様の表現およびこれらの用語の否定を含むが、前向き表現を使用することによって識別することができる。これらの表現は未来の事件或いは会社の財務表現に関連し、既知と未知のリスク、不確定要素とその他の要素に関連し、新冠肺炎疫病の会社の運営、臨床発展計画とスケジュールに対する潜在的な影響を含み、会社のある候補製品の場外取引ルートへのいかなる転換を含み、これは実際の結果、業績或いは成果と展望性表現の中で明示或いは暗示する未来の結果、業績或いは成果が大きく異なることを招く可能性がある。これらの要素は、同社が証券取引委員会に提出した文書に記載されている要素を含む。このような前向きな陳述に過度に依存しないように潜在的投資家を戒める。これらの陳述は、本プレスリリースの発表日にのみ発表される。会社は、新しい情報、未来の事件、その他の理由でも、いかなる前向きな陳述も公開更新する義務を負わない
VIRPAX製薬会社 |
簡明貸借対照表 |
| | 六月三十日 2022 | | 十二月三十一日 2021* |
| | (未監査) | | | |
資産 | | | | | | |
流動資産 | | | | | | |
現金 | | $ | 26,061,135 | | | $ | 36,841,992 | |
前払い費用と他の流動資産 | | | 3,341,307 | | | | 2,730,444 | |
流動資産総額 | | | 29,402,442 | | | | 39,572,436 | |
総資産 | | $ | 29,402,442 | | | $ | 39,572,436 | |
負債と株主権益 | | | | | | | | |
売掛金と売掛金 | | $ | 2,483,373 | | | $ | 2,087,691 | |
流動負債総額 | | | 2,483,373 | | | | 2,087,691 | |
総負債 | | | 2,483,373 | | | | 2,087,691 | |
引受金とその他の事項 | | | | | | | | |
株主権益 | | | | | | | | |
優先株、額面0.00001ドル、指定株式10,000,000株、発行済み株式なし | | | — | | | | — | |
普通株、額面0.00001ドル;授権株100,000,000株、2022年6月30日現在発行·発行済み株11,714,565株;2021年12月31日現在発行済み株11,714,885株 | | | 117 | | | | 117 | |
追加実収資本 | | | 60,644,576 | | | | 60,188,535 | |
赤字を累計する | | | (33,725,624 | ) | | | (22,703,907 | ) |
株主権益総額 | | | 26,919,069 | | | | 37,484,745 | |
総負債と株主権益 | | $ | 29,402,442 | | | $ | 39,572,436 | |
VIRPAX製薬会社 |
業務簡明報告書 |
(未監査) |
| | 3人にとっては 現在までの月 六月三十日 2022 | | 3人にとっては 現在までの月 六月三十日 2021 | | 6人に 現在までの月 六月三十日 2022 | | 6人に 現在までの月 六月三十日 2021 |
運営費 | | | | | | | | | | | | | | | | |
一般と行政 | | $ | 2,645,618 | | | $ | 1,988,972 | | | $ | 4,428,031 | | | $ | 3,262,544 | |
研究開発 | | | 3,258,471 | | | | 316,565 | | | | 6,599,877 | | | | 1,391,565 | |
総運営費 | | | 5,904,089 | | | | 2,305,537 | | | | 11,027,908 | | | | 4,654,109 | |
運営損失 | | | (5,904,089 | ) | | | (2,305,537 | ) | | | (11,027,908 | ) | | | (4,654,109 | ) |
その他の収入 | | | | | | | | | | | | | | | | |
利子支出 | | | - | | | | (34,049 | ) | | | - | | | | (64,748 | ) |
その他の収入,純額 | | | 19,374 | | | | (3,833 | ) | | | 6,191 | | | | (3,833 | ) |
税引き前損失準備 | | | (5,884,715 | ) | | | (2,343,419 | ) | | | (11,021,717 | ) | | | (4,722,690 | ) |
所得税から利益を得る | | | — | | | | — | | | | — | | | | — | |
純損失 | | $ | (5,884,715 | ) | | $ | (2,343,419 | ) | | $ | (11,021,717 | ) | | $ | (4,722,690 | ) |
1株当たりの基本と償却純損失 | | | $ (0.50 | ) | | | $ (0.47 | ) | | $ | (0.94 | ) | | $ | (1.06 | ) |
基本と希釈加重平均普通株式を発行しました | | | 11,712,753 | | | | 4,958,999 | | | | 11,710,733 | | | | 4,454,877 | |
VIRPAX製薬会社 |
簡明現金フロー表 |
(未監査) |
| | 6人に 現在までの月 六月三十日 2022 | | 6人に 現在までの月 六月三十日 2021 |
経営活動のキャッシュフロー | | | | | | | | |
純損失 | | $ | (11,021,717 | ) | | $ | (4,722,690 | ) |
純損失と経営活動で使用される現金純額の調整: | | | | | | | | |
非現金利子支出 | | | — | | | | 64,748 | |
株に基づく報酬 | | | 456,041 | | | | 691,311 | |
営業資産と負債の変動: | | | | | | | | |
前払い費用と他の流動資産 | | | (610,863 | ) | | | (902,649 | ) |
売掛金と売掛金 | | | 395,682 | | | | (8,469 | ) |
経営活動のための現金純額 | | | (10,780,857 | ) | | | (4,877,749 | ) |
融資活動によるキャッシュフロー | | | | | | | | |
支払手形の償還 | | | — | | | | (493,480 | ) |
関連側手形利得に対応する | | | — | | | | 100,000 | |
関係者支払手形を償還する | | | — | | | | (100,000 | ) |
初公募株に関する発行コスト | | | — | | | | (2,216,793 | ) |
普通株で得た金を初めて公開発行する | | | — | | | | 18,000,000 | |
融資活動が提供する現金純額 | | | — | | | | 15,289,727 | |
現金純変動額 | | | (10,780,857 | ) | | | 10,411,978 | |
期初の現金 | | | 36,841,992 | | | | 54,796 | |
期末現金 | | $ | 26,061,135 | | | $ | 10,466,774 | |
現金と非現金融資活動を補完開示する | | | | | | | | |
利子を支払う現金 | | $ | — | | | $ | 34,707 | |
税金の現金を納める | | $ | — | | | $ | — | |
連絡先 公認会計士クリストファー·M·チップマン
首席財務官
メールボックス:cchipman@virpaxpharma.com
610-727-4597
あるいは…。
ベッキー·ブロダー
親和力成長コンサルタント
メールボックス:betsys.brod@affinityrowth.com
212-661-2231